Latest Insider Transactions at Altimmune, Inc. (ALT)
This section provides a real-time view of insider transactions for Altimmune, Inc. (ALT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Altimmune, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Altimmune, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2022
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,183
-15.9%
|
$15,281
$7.98 P/Share
|
|
Feb 01
2022
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+30.99%
|
-
|
|
Jan 31
2022
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,106
+13.31%
|
$12,636
$6.86 P/Share
|
|
Jan 31
2022
|
Vipin K Garg President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,757
+0.96%
|
$16,542
$6.86 P/Share
|
|
Jan 31
2022
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+19.23%
|
$10,800
$6.86 P/Share
|
|
Jan 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,355
-0.83%
|
$16,485
$7.2 P/Share
|
|
Jan 25
2022
|
David Drutz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
70
+0.39%
|
$140
$2.4 P/Share
|
|
Dec 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.05%
|
$24,056
$8.93 P/Share
|
|
Dec 14
2021
|
David Drutz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
139
+0.77%
|
$278
$2.4 P/Share
|
|
Nov 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.04%
|
$30,070
$10.49 P/Share
|
|
Nov 19
2021
|
David Drutz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
70
+0.39%
|
$140
$2.4 P/Share
|
|
Oct 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.03%
|
$30,070
$10.8 P/Share
|
|
Sep 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.02%
|
$33,077
$11.31 P/Share
|
|
Aug 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,008
-1.01%
|
$42,112
$14.09 P/Share
|
|
Jul 31
2021
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,750
+13.1%
|
$12,250
$7.71 P/Share
|
|
Jul 31
2021
|
William Michael Brown Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
803
+4.33%
|
$5,621
$7.71 P/Share
|
|
Jul 31
2021
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
725
+11.18%
|
$5,075
$7.71 P/Share
|
|
Jul 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.0%
|
$27,063
$9.07 P/Share
|
|
Jun 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-0.99%
|
$27,063
$9.85 P/Share
|
|
May 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,577
-0.84%
|
$30,924
$12.65 P/Share
|
|
Apr 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,999
-0.65%
|
$27,986
$14.47 P/Share
|
|
Mar 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,998
-0.64%
|
$25,974
$13.55 P/Share
|
|
Mar 01
2021
|
Philip Hodges Director |
SELL
Open market or private sale
|
Direct |
6,000
-40.73%
|
$96,000
$16.08 P/Share
|
|
Feb 28
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,998
-0.64%
|
$29,970
$15.94 P/Share
|
|
Feb 25
2021
|
Venrock Healthcare Capital Partners Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,000,000
-22.22%
|
-
|
|
Jan 31
2021
|
Vipin K Garg President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,055
+0.34%
|
$12,660
$12.14 P/Share
|
|
Jan 31
2021
|
William Michael Brown Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
937
+5.25%
|
$11,244
$12.14 P/Share
|
|
Jan 31
2021
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
467
+4.52%
|
$5,604
$12.14 P/Share
|
|
Jan 31
2021
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
968
+16.12%
|
$11,616
$12.14 P/Share
|
|
Jan 30
2021
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,353
-0.75%
|
$32,942
$14.28 P/Share
|
|
Dec 30
2020
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,025
-0.95%
|
$33,275
$11.3 P/Share
|
|
Dec 10
2020
|
Klaus Schafer Director |
BUY
Open market or private purchase
|
Direct |
2,000
+18.35%
|
$22,000
$11.99 P/Share
|
|
Dec 01
2020
|
Philip Hodges Director |
SELL
Open market or private sale
|
Indirect |
1,227
-100.0%
|
$15,951
$13.54 P/Share
|
|
Nov 30
2020
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,243
-0.7%
|
$26,916
$12.23 P/Share
|
|
Nov 30
2020
|
John Gill Director |
SELL
Open market or private sale
|
Direct |
8,425
-42.93%
|
$92,675
$11.92 P/Share
|
|
Nov 30
2020
|
Philip Hodges Director |
SELL
Open market or private sale
|
Direct |
2,500
-14.51%
|
$30,000
$12.0 P/Share
|
|
Nov 13
2020
|
David Drutz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
60
+0.34%
|
$120
$2.4 P/Share
|
|
Nov 12
2020
|
Matthew Scott Harris Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,015
-49.67%
|
$40,150
$10.02 P/Share
|
|
Nov 12
2020
|
Wayne Pisano Director |
SELL
Open market or private sale
|
Direct |
10,352
-54.92%
|
$93,168
$9.9 P/Share
|
|
Nov 12
2020
|
Klaus Schafer Director |
SELL
Open market or private sale
|
Direct |
10,150
-59.53%
|
$91,350
$9.91 P/Share
|
|
Oct 30
2020
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,015
-0.63%
|
$22,165
$11.45 P/Share
|
|
Sep 30
2020
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,015
-0.62%
|
$26,195
$13.2 P/Share
|
|
Sep 24
2020
|
Philip Hodges Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,850
+31.7%
|
-
|
|
Sep 24
2020
|
Klaus Schafer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,850
+49.71%
|
-
|
|
Sep 24
2020
|
David Drutz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,850
+48.99%
|
-
|
|
Sep 24
2020
|
Wayne Pisano Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,850
+47.2%
|
-
|
|
Sep 24
2020
|
John Gill Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,850
+46.2%
|
-
|
|
Sep 24
2020
|
Mitchel Sayare Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,275
+48.95%
|
-
|
|
Sep 12
2018
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
2,069,993
+19.87%
|
-
|
|
Jul 11
2018
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
663,346
+9.56%
|
-
|